AMArnaud Métais

Arnaud Métais

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arnaud Métais has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dual human lung models reveal compartment-specific activity of anti-tuberculosis drugs and host-directed therapies

    by Caio César Barbosa Bomfim, Natacha Faivre, Thomas Benoist, Manon Popis, Bastien Suire, David Pericat, José Manuel Sánchez-López, Beatriz Melissa Aponte-Castillo, Emmanuelle Näser, Pénélope Viana, et al.

    Tuberculosis (TB) remains a major global health challenge that requires new therapeutic strategies to improve drug efficacy, shorten treatment duration, prevent drug resistance, and limit Mycobacterium tuberculosis (Mtb) persistence. Here, we established complementary in vitro human lung models integrating alveolar macrophage-like (AML) cells and airway air–liquid interface (ALI) cultures to evaluate standard-of-care antibiotics, host-directed therapies, and virulence-targeting agents. AMLs recapitulated key morphological, transcriptional, and functional features of primary alveolar macrophages, including a CD16 + immunoregulatory phenotype highly permissive to Mtb infection. In parallel, ALI cultures maintained epithelial barrier integrity and secretory functions, allowing apical Mtb infection, drug penetration analysis, and inflammatory profiling. Benchmarking of standard-of-care antibiotics revealed compartment-specific activity: isoniazid, rifampicin, and moxifloxacin were effective in both systems, while pyrazinamide was active only in AMLs. Anti-inflammatory host-directed therapies, such as ibuprofen and doramapimod, selectively reduced cytokine production without affecting bacterial load. Together, this dual-platform system offers a physiologically relevant and scalable model to assess antimicrobial efficacy and host modulation across distinct pulmonary niches, bridging the gap between conventional macrophage assays and the complex human lung. IMPORTANCE: Tuberculosis remains one of the world's deadliest infectious diseases. The development of new therapies is limited by the absence of human-relevant models that reproduce the distinct lung niches encountered by Mycobacterium tuberculosis . Current macrophage or epithelial monocultures fail to predict how drugs act in the alveolar versus airway compartments, where intracellular and extracellular bacteria coexist and trigger different immune responses. Here, we introduce a dual human lung platform integrating alveolar macrophage-like cells and air–liquid interface airway epithelium. These models recapitulate key physiological features, including macrophage immunoregulatory programming, epithelial barrier function, mucociliary activity, and compartment-specific drug penetration. Benchmarking standard antibiotics, host-directed therapies, and antivirulence strategies revealed striking niche-dependent differences in antimicrobial and immunomodulatory activities. This system provides a powerful and accessible preclinical tool to evaluate antimicrobial and host-directed interventions in relevant human lung environments, helping bridge the gap between simplified in vitro assays and the complex biology of human tuberculosis.


  • Open Access

    Dual human lung models reveal compartment-specific activity of anti-tuberculosis drugs and host-directed therapies

    by Caio César Barbosa Bomfim, Natacha Faivre, Thomas Benoist, Manon Popis, Bastien Suire, David Pericat, José Manuel Sánchez-López, Beatriz Melissa Aponte-Castillo, Emmanuelle Näser, Pénélope Viana, et al.

    SUMMARY: Tuberculosis (TB) remains a major global health challenge that requires new therapeutic strategies to improve drug efficacy, shorten treatment duration, prevent drug resistance, and limit Mycobacterium tuberculosis (Mtb) persistence. Here, we established complementary in vitro human lung models integrating alveolar macrophage-like (AML) cells and airway air-liquid interface (ALI) cultures to evaluate standard-of-care antibiotics, host-directed therapies, and virulence-targeting agents. AMLs recapitulated key morphological, transcriptional, and functional features of primary alveolar macrophages, including a CD16 + immunoregulatory phenotype highly permissive to Mtb infection. In parallel, ALI cultures maintained epithelial barrier integrity and secretory functions, allowing apical Mtb infection, drug penetration analysis, and inflammatory profiling. Benchmarking of standard-of-care antibiotics revealed compartment-specific activity: isoniazid, rifampicin, and moxifloxacin were effective in both systems, while pyrazinamide was active only in AMLs. Anti-inflammatory host-directed therapies such as ibuprofen and doramapimod selectively reduced cytokine production without affecting bacterial load. Together, this dual-platform system offers a physiologically relevant and scalable model to assess antimicrobial efficacy and host modulation across distinct pulmonary niches, bridging the gap between conventional macrophage assays and the complex human lung.

  • Open Access

    Moesin controls cell–cell fusion and osteoclast function

    by Ophélie Dufrançais, Marianna Plozza, Marie Juzans, Arnaud Métais, Sarah C. Monard, Pierre-Jean Bordignon, Perrine Verdys, Thibaut Sanchez, Martin Bergert, Julia Halper, et al.

    Cell–cell fusion is an evolutionarily conserved process that is essential for many functions, including the formation of bone-resorbing multinucleated osteoclasts. Osteoclast multinucleation involves dynamic interactions between the actin cytoskeleton and the plasma membrane that are still poorly characterized. We found that moesin, a cytoskeletal linker protein member of the Ezrin, radixin, and moesin (ERM) protein family, plays a critical role in both osteoclast fusion and function. Moesin inhibition favors osteoclast multinucleation as well as HIV-1- and inflammation-induced cell fusion. Accordingly, moesin depletion decreases membrane-to-cortex attachment and enhances the formation of tunneling nanotubes, F-actin–based intercellular bridges triggering cell–cell fusion. In addition, moesin regulates the formation of the sealing zone, a key structure determining osteoclast bone resorption area, and thus controls bone degradation via a β3-integrin/RhoA/SLK pathway. Finally, moesin-deficient mice have reduced bone density and increased osteoclast abundance and activity. These findings provide a better understanding of cell–cell fusion and osteoclast biology, opening new opportunities to specifically target osteoclasts in bone disease therapy.


  • Open Access

    Fine-tuning levels of filamins a and b as a specific mechanism sustaining Th2 lymphocyte functions

    by Kilian Maire, Léa Chamy, Samira Ghazali, Manon Carratala-Lasserre, Margot Zahm, Clément Bouisset, Arnaud Métais, Lucie Combes-Soia, Lidia de la Fuente-Vizuete, Hussein Trad, et al.

    Augmenting the portfolio of therapeutics for type 2-driven diseases is crucial to address unmet clinical needs and to design personalized treatment schemes. An attractive therapy for such diseases would consist in targeting the recruitment of T helper 2 (Th2) lymphocytes to inflammatory sites. Herein, we show the degradation of filamins (FLN) a and b by the ASB2α E3 ubiquitin ligase as a mechanism sustaining Th2 lymphocyte functions. Low levels of FLNa and FLNb confer an elongated shape to Th2 lymphocytes associated with efficient αVβ3 integrin-dependent cell migration. Genes encoding the αVβ3 integrin and ASB2α belong to the core of Th2-specific genes. Using genetically modified mice, we find that increasing the levels of FLNa and FLNb in Th2 lymphocytes reduces airway inflammation through diminished Th2 lymphocyte recruitment in inflamed lungs. Collectively, our results highlight ASB2α and its substrates FLNa and FLNb to alter Th2 lymphocyte-mediated responses.


  • Open Access

    Productive HIV-1 infection of tissue macrophages by fusion with infected CD4+ T cells

    by Rémi Mascarau, Marie Woottum, Léa Fromont, Rémi Gence, Vincent Cantaloube-Ferrieu, Zoï Vahlas, Kevin Lévêque, Florent Bertrand, Thomas Beunon, Arnaud Métais, et al.

    Macrophages are essential for HIV-1 pathogenesis and represent major viral reservoirs. Therefore, it is critical to understand macrophage infection, especially in tissue macrophages, which are widely infected in vivo, but poorly permissive to cell-free infection. Although cell-to-cell transmission of HIV-1 is a determinant mode of macrophage infection in vivo, how HIV-1 transfers toward macrophages remains elusive. Here, we demonstrate that fusion of infected CD4+ T lymphocytes with human macrophages leads to their efficient and productive infection. Importantly, several tissue macrophage populations undergo this heterotypic cell fusion, including synovial, placental, lung alveolar, and tonsil macrophages. We also find that this mode of infection is modulated by the macrophage polarization state. This fusion process engages a specific short-lived adhesion structure and is controlled by the CD81 tetraspanin, which activates RhoA/ROCK-dependent actomyosin contractility in macrophages. Our study provides important insights into the mechanisms underlying infection of tissue-resident macrophages, and establishment of persistent cellular reservoirs in patients.